3 research outputs found
Agreement of body adiposity index (BAI), bioimpedance analysis and ultrasound scanning in determining body fat
BACKGROUND: The steadily increasing number of people with obesity requires the development of simple and accurate methodological approaches to assess the absolute and relative amount of body fat mass. The body adiposity index (BAI) is one of the indices proposed to assess the body fat percentage. However, the comparison analysis of common methods, i.e., of bio-electrical impedance analysis and ultrasound scanning, and BAI was not performed for the Russian population.AIM: Comparison analysis of the body fat percentage estimates by bio-electrical impedance analysis, ultrasound scanning, and body adiposity index in the group of adult male and females.MATERIALS AND METHODS: An examination of healthy males and females from Moscow was conducted. Height, weight, waist and hip circumferences were measured. The body fat percentage was obtained by bio-electrical impedance analysis β BIA (ABC-02 Medas), ultrasound scanning β US (BodyMetrixTM, IntelaMetrix), and body adiposity index.RESULTS: 263 females and 134 males aged 18 to 73 years participated in the study. Correlation coefficients between BAI values and the body fat percentage obtained by BIA and US were 0.749 and 0.763 (p<0.000), respectively. Comparison of body fat percentage measurements obtained by BAI, BIA and US showed the low agreement (Π‘Π‘Π‘<0.90) between BAI and other methods in pooled sample as well as in the female and male groups. Comparison of the US and BAI methods revealed higher level of agreement (Π‘Π‘Π‘=0.84 [0.80β0.86]) and no systematic bias. Lower level of agreement was obtained in the group of males.CONCLUSION: Conducted study allows to conclude that, at the individual level, BAI is not an appropriate method for estimating the body fat percentage relatively to other indirect methods. However, all three methods can be used in the group of pooled males and females when testing at the population level
Possibilities of interferon induced neutropenia treatment for patients with chronic hepatitis Π‘
The aim of our study was to estimate the effectiveness of Russian medicament Licopid to treat interferon-induced neutropenia in patients with chronic hepatitis C. The study included 21 patients with moderate and severe neutropenia during standard antiviral therapy. Genotype 1 HCV were 52.4% of patients, patients with non-genotype 1 was 47.6%. Pegylated IFN-a and ribavirin received 12 patients, standard IFN-a and ribavirin - 9 patients. Likopid was administered at a dosage of 20 mg per day for 20 days. In all patients during treatment with Likopid there was clinically meaningful and reliable growth the number of peripheral blood neutrophils to the 10th and/or 20th day of therapy. In most patients, the positive effect lasted for at least 30 days after discontinuation of the Likopid. We found that Likopid is effective regardless of genotype HCV, baseline viral load and the type of interferon. During treatment with Licopid patients had no need to take modify doses of antiviral medicine.Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΈΠΊΠΎΠΏΠΈΠ΄, Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π²ΠΈΡΡΡΠ½ΡΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ» Π²ΠΊΠ»ΡΡΠ΅Π½ 21 ΠΏΠ°ΡΠΈΠ΅Π½Ρ Ρ Π½Π΅ΠΉΡΡΠΎΠΏΠ΅Π½ΠΈΠ΅ΠΉ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π½Π° ΡΠΎΠ½Π΅ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ΅Π½ΠΎΡΠΈΠΏ 1 Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ ΠΈΠΌΠ΅Π»ΠΈ 52,4% Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π½Π΅ 1 Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠΌ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 47,6%. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠ΅Π³ΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΠΠ€Π-Π° ΠΈ ΡΠΈΠ±Π°Π²ΠΈΡΠΈΠ½ΠΎΠΌ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ 12 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΌ ΠΠ€Π-Ξ± ΠΈ ΡΠΈΠ±Π°Π²ΠΈΡΠΈΠ½ΠΎΠΌ - 9 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ. ΠΠΈΠΊΠΎΠΏΠΈΠ΄ Π½Π°Π·Π½Π°ΡΠ°Π»ΡΡ Π² Π΄ΠΎΠ·ΠΈΡΠΎΠ²ΠΊΠ΅ 20 ΠΌΠ³ Π² ΡΡΡΠΊΠΈ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 20 Π΄Π½Π΅ΠΉ. Π£ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π½Π° ΡΠΎΠ½Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠΈΠΊΠΎΠΏΠΈΠ΄ΠΎΠΌ Π½Π°Π±Π»ΡΠ΄Π°Π»ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΉ ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΉ ΡΠΎΡΡ ΡΠΈΡΠ»Π° Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΠΎΠ² ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΊ 10-ΠΌΡ ΠΈ/ΠΈΠ»ΠΈ 20-ΠΌΡ Π΄Π½Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π£ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΡΠΎΡ
ΡΠ°Π½ΡΠ»ΡΡ ΠΏΠΎ ΠΌΠ΅Π½ΡΡΠ΅ΠΉ ΠΌΠ΅ΡΠ΅ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 30 Π΄Π½Π΅ΠΉ ΠΏΠΎΡΠ»Π΅ ΠΎΡΠΌΠ΅Π½Ρ ΠΠΈΠΊΠΎΠΏΠΈΠ΄Π°. ΠΠ°ΠΌΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΠΈΠΊΠΎΠΏΠΈΠ΄ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ Π΄Π΅ΠΉΡΡΠ²ΡΠ΅Ρ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° Π²ΠΈΡΡΡΠ°, ΠΈΡΡ
ΠΎΠ΄Π½ΠΎΠΉ Π²ΠΈΡΡΡΠ½ΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΈ ΠΈ ΡΠΈΠΏΠ° ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°. ΠΠΎ Π²ΡΠ΅ΠΌΡ Π΅Π³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½Π΅ ΠΏΠΎΡΡΠ΅Π±ΠΎΠ²Π°Π»Π°ΡΡ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π΄ΠΎΠ·Ρ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Ξ±